Welcome to our dedicated page for Neuronetics SEC filings (Ticker: STIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neuronetics, Inc. filings document the public reporting record for a Nasdaq-listed medical technology and healthcare company with common stock traded under STIM. Recent Form 8-K reports furnish operating results, investor presentation materials, executive appointments and retirements, compensation arrangements, restructuring charges, and material agreements tied to credit facilities and registration rights.
The company’s proxy materials describe annual meeting voting matters, director elections, auditor ratification, advisory executive compensation votes, and equity incentive plan approvals. Together with event reports, the filings disclose governance procedures, capital-structure matters, Nasdaq-listed security information, and contractual obligations associated with Neuronetics’ medical device and clinic-services operations.
Neuronetics, Inc. major shareholder Jorey Chernett reported an open-market purchase of 531,000 shares of common stock at a weighted average price of $1.16 per share. The filing notes the shares were bought in multiple trades between $0.91 and $1.31 per share. Following this transaction, Chernett directly owns 7,516,404 shares of Neuronetics common stock.
Neuronetics, Inc. reported that significant shareholder Jorey Chernett beneficially owns 6,985,404 shares of the company’s common stock. This Form 3 filing is an initial statement of holdings by a more than ten percent owner and does not reflect any new share transactions.
Neuronetics, Inc. filing amends beneficial ownership disclosure for Jorey Chernett. As of the close of business on March 17, 2026, the Reporting Person beneficially owned 7,516,404 shares of Common Stock, representing 10.85% of the class based on 69,276,593 Shares outstanding as of March 10, 2026.
The amendment updates the Schedule 13G/A ownership figures and reports sole voting and dispositive power over the disclosed shares. The statement is signed and dated 03/18/2026.
Neuronetics, Inc. registers up to 20,737,061 shares of its common stock for resale by selling stockholders pursuant to a shelf prospectus dated March 17, 2026.
The prospectus states the Company will receive no proceeds from these sales and identifies Madryn-related entities as the primary selling stockholders, who beneficially owned a combined portion of outstanding shares as of March 10, 2026. The filing describes distribution methods, indemnities, and that the shares represent a significant percentage of outstanding common stock, which could affect market price if sold concurrently.
Neuronetics, Inc. registers up to 20,737,061 shares of its common stock for resale by selling stockholders pursuant to a shelf prospectus dated March 17, 2026.
The prospectus states the Company will receive no proceeds from these sales and identifies Madryn-related entities as the primary selling stockholders, who beneficially owned a combined portion of outstanding shares as of March 10, 2026. The filing describes distribution methods, indemnities, and that the shares represent a significant percentage of outstanding common stock, which could affect market price if sold concurrently.
Neuronetics, Inc. ownership filing: Parian Ultreia reports beneficial ownership of 4,844,908 shares, equal to 7.0% of the class, with sole voting and dispositive power over those shares. The filing is signed by Portfolio Manager Zachary Miller on 03/17/2026.
Neuronetics, Inc. ownership filing: Parian Ultreia reports beneficial ownership of 4,844,908 shares, equal to 7.0% of the class, with sole voting and dispositive power over those shares. The filing is signed by Portfolio Manager Zachary Miller on 03/17/2026.
Neuronetics, Inc. reports strong 2025 growth while remaining unprofitable as it integrates Greenbrook TMS. Revenue reached $149.2 million for the year ended December 31, 2025, up 99% from 2024, driven largely by its NeuroStar TMS platform and newly acquired Greenbrook treatment centers.
U.S. revenue was $146.0 million, up 101% year over year. Clinic revenue rose to 59% of U.S. revenue from 6% as Neuronetics shifted toward operating 93 Greenbrook treatment centers, while treatment-session revenue fell to 30% from 70%. The company still posted a net loss of $39.1 million and has an accumulated deficit of $458.8 million, highlighting ongoing profitability and integration challenges despite rapid top-line expansion.
Neuronetics, Inc. reports strong 2025 growth while remaining unprofitable as it integrates Greenbrook TMS. Revenue reached $149.2 million for the year ended December 31, 2025, up 99% from 2024, driven largely by its NeuroStar TMS platform and newly acquired Greenbrook treatment centers.
U.S. revenue was $146.0 million, up 101% year over year. Clinic revenue rose to 59% of U.S. revenue from 6% as Neuronetics shifted toward operating 93 Greenbrook treatment centers, while treatment-session revenue fell to 30% from 70%. The company still posted a net loss of $39.1 million and has an accumulated deficit of $458.8 million, highlighting ongoing profitability and integration challenges despite rapid top-line expansion.
Neuronetics, Inc. reported strong growth for Q4 and full-year 2025 alongside a leadership change. Q4 2025 revenue was $41.8 million, up 86% from Q4 2024, driven mainly by the Greenbrook clinic acquisition. Full-year 2025 revenue nearly doubled to $149.2 million from $74.9 million, with U.S. revenue up 101%.
Profitability remains a challenge: full-year gross margin fell to 48.5% from 72.3%, and net loss was $(39.1) million, an improvement from $(43.7) million. The company ended 2025 with $34.1 million in cash and restricted cash and generated $0.9 million of operating cash in Q4.
The board appointed Dan Reuvers as President and CEO effective March 23, 2026, with an initial base salary of $730,000 and a grant of 1.5 million RSUs. For 2026, Neuronetics guides to revenue of $160–$166 million, expects operating expenses of $100–$105 million, and anticipates significantly improved operating cash flow as efficiency initiatives and the Greenbrook integration progress.
Neuronetics, Inc. reported strong growth for Q4 and full-year 2025 alongside a leadership change. Q4 2025 revenue was $41.8 million, up 86% from Q4 2024, driven mainly by the Greenbrook clinic acquisition. Full-year 2025 revenue nearly doubled to $149.2 million from $74.9 million, with U.S. revenue up 101%.
Profitability remains a challenge: full-year gross margin fell to 48.5% from 72.3%, and net loss was $(39.1) million, an improvement from $(43.7) million. The company ended 2025 with $34.1 million in cash and restricted cash and generated $0.9 million of operating cash in Q4.
The board appointed Dan Reuvers as President and CEO effective March 23, 2026, with an initial base salary of $730,000 and a grant of 1.5 million RSUs. For 2026, Neuronetics guides to revenue of $160–$166 million, expects operating expenses of $100–$105 million, and anticipates significantly improved operating cash flow as efficiency initiatives and the Greenbrook integration progress.
Neuronetics, Inc. executive William Andrew Macan, EVP, CLO and CS, reported a small automatic share sale tied to equity compensation. On March 4, 2026, he disposed of 609 shares of common stock in open-market transactions at a weighted average price of $1.34 per share, with individual prices ranging from $1.28 to $1.39. The footnotes state these were non-discretionary sales made solely to satisfy his tax withholding obligation upon the vesting of a restricted stock unit award. After this tax-related sale, he continued to own 879,525 common shares directly.
Madryn-affiliated investment funds report a major stake in Neuronetics, Inc., holding 20,737,061 shares of common stock, or about 30.3% of the company. These percentages are based on 68,485,922 shares outstanding as of October 29, 2025, from Neuronetics’ Form 10-Q.
The filing describes a Registration Rights Agreement, as amended, giving Madryn parties registration and piggyback rights for their consideration shares. Madryn has agreed not to acquire additional Neuronetics equity or convertible debt and to vote all of its shares at the 2026 annual meeting in line with the board’s recommendations on specified proposals.
STIM filed a Form 144 notifying proposed sales of common stock by an insider. The notice lists proposed transactions tied to restricted stock vesting and identifies prior open-market dispositions by William A. Macan of 3,485, 14,120, and 3,427 common shares on 02/10/2026, 02/12/2026, and 02/26/2026, respectively.
The filing names Fidelity Brokerage Services LLC as broker and records an entry dated 03/04/2026 on NASDAQ. The Form indicates securities arising from restricted stock vesting dated 02/27/2026 and labels the grant as compensation.